Leishmaniasis: current status of available drugs and new potential drug targets
The control of Leishmania infection relies primarily on chemotherapy till date. Resistance to
pentavalent antimonials, which have been the recommended drugs to treat cutaneous and …
pentavalent antimonials, which have been the recommended drugs to treat cutaneous and …
Use of antimony in the treatment of leishmaniasis: current status and future directions
In the recent past the standard treatment of kala‐azar involved the use of pentavalent
antimonials Sb (V). Because of progressive rise in treatment failure to Sb (V) was limited its …
antimonials Sb (V). Because of progressive rise in treatment failure to Sb (V) was limited its …
Natural product based leads to fight against leishmaniasis
The growing incidence of parasitic resistance against generic pentavalent antimonials,
specifically for visceral disease in Indian subcontinent, is a serious issue in Leishmania …
specifically for visceral disease in Indian subcontinent, is a serious issue in Leishmania …
Leishmania–macrophage interactions: Insights into the redox biology
Leishmaniasis is a neglected tropical disease that affects about 350 million individuals
worldwide. The protozoan parasite has a relatively simple life cycle with two principal …
worldwide. The protozoan parasite has a relatively simple life cycle with two principal …
Drug resistance in visceral leishmaniasis
HC Maltezou - BioMed Research International, 2010 - Wiley Online Library
Visceral leishmaniasis remains a public health problem worldwide. This illness was
included by the World Health Organization in the list of neglected tropical diseases targeted …
included by the World Health Organization in the list of neglected tropical diseases targeted …
Molecular mechanisms of antimony resistance in Leishmania
Leishmaniasis causes significant morbidity and mortality worldwide. The disease is endemic
in developing countries of tropical regions, and in recent years economic globalization and …
in developing countries of tropical regions, and in recent years economic globalization and …
Cutaneous leishmaniasis: advances in disease pathogenesis, diagnostics and therapeutics
M Ameen - Clinical and experimental dermatology, 2010 - academic.oup.com
Cutaneous leishmaniasis is one of the most common tropical dermatoses worldwide and is
of major public health importance. It is caused by numerous Leishmania protozoa species …
of major public health importance. It is caused by numerous Leishmania protozoa species …
Leishmaniasis: prevention, parasite detection and treatment
T Kobets, I Grekov, M Lipoldova - Current Medicinal Chemistry, 2012 - ingentaconnect.com
Leishmaniasis remains a public health problem worldwide, affecting approximately 12
million people in 88 countries; 50 000 die of it each year. The disease is caused by …
million people in 88 countries; 50 000 die of it each year. The disease is caused by …
Antimicrobials and resistance part II: Antifungals, antivirals, and antiparasitics
FF Muhaj, SJ George, CD Nguyen, SK Tyring - Journal of the American …, 2022 - Elsevier
The available antifungal armamentarium consists of only a few drug classes, many limited in
their use by significant toxicities and dangerous drug interactions. Rising opportunistic …
their use by significant toxicities and dangerous drug interactions. Rising opportunistic …
Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to …
Background Miltefosine (MIL) is an oral antileishmanial drug used for treatment of visceral
leishmaniasis (VL) in the Indian subcontinent. Recent reports indicate a significant decline in …
leishmaniasis (VL) in the Indian subcontinent. Recent reports indicate a significant decline in …